Humana (NYSE:HUM) Updates FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of approx. $16.00 for the period, compared to the consensus EPS estimate of $16.35.

Humana Price Performance

Shares of NYSE:HUM opened at $305.91 on Friday. The company has a market cap of $36.86 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 1.82 and a beta of 0.45. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The firm has a 50 day simple moving average of $327.77 and a 200 day simple moving average of $394.49. Humana has a one year low of $299.23 and a one year high of $541.21.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.38 EPS. Research analysts predict that Humana will post 16.07 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Argus cut shares of Humana from a buy rating to a hold rating in a research report on Wednesday, March 13th. Wells Fargo & Company decreased their price objective on shares of Humana from $413.00 to $350.00 and set an overweight rating for the company in a research report on Monday, April 8th. Bank of America reiterated a neutral rating and set a $342.00 price objective (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Royal Bank of Canada reduced their price target on shares of Humana from $415.00 to $353.00 and set an outperform rating for the company in a report on Thursday. Finally, Mizuho reduced their price target on shares of Humana from $550.00 to $400.00 and set a buy rating for the company in a report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus price target of $433.74.

Insider Transactions at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the stock in a transaction dated Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.